

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Marston, M; Nakiyingi-Miir, J; Hosegood, V; Lutalo, T; Mtenga, B; Zaba, B; ALPHA network (2016) Measuring the Impact of Antiretroviral Therapy Roll-Out on Population Level Fertility in Three African Countries. PLoS One, 11 (3). e0151877. ISSN 1932-6203 DOI: 10.1371/journal.pone.0151877

Downloaded from: <http://researchonline.lshtm.ac.uk/2535792/>

DOI: [10.1371/journal.pone.0151877](https://doi.org/10.1371/journal.pone.0151877)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by/2.5/>

RESEARCH ARTICLE

Measuring the Impact of Antiretroviral Therapy Roll-Out on Population Level Fertility in Three African Countries

Milly Marston^{1*}, Jessica Nakiyingi-Miir², Victoria Hosegood^{3,4}, Tom Lutalo⁵, Baltazar Mtenga⁶, Basia Zaba¹, on behalf of the ALPHA network[¶]

1 London School of Hygiene and Tropical Medicine, London, United Kingdom, **2** Medical Research Council, Entebbe, Uganda, **3** Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, **4** Faculty of Medicine, Faculty of Social and Human Sciences, University of Southampton, Southampton, United Kingdom, **5** TAZAMA Project, National Institute of Medical Research, Mwanza, Tanzania, **6** Rakai Health Sciences Program, Kalisizo, Rakai, Uganda

[¶] Membership of the ALPHA network is provided in the Acknowledgments.

* milly.marston@lshtm.ac.uk



OPEN ACCESS

Citation: Marston M, Nakiyingi-Miir J, Hosegood V, Lutalo T, Mtenga B, Zaba B, et al. (2016) Measuring the Impact of Antiretroviral Therapy Roll-Out on Population Level Fertility in Three African Countries. PLoS ONE 11(3): e0151877. doi:10.1371/journal.pone.0151877

Editor: Stephane Helleringer, Johns Hopkins University, UNITED STATES

Received: June 29, 2015

Accepted: March 4, 2016

Published: March 25, 2016

Copyright: © 2016 Marston et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Aggregated data are provided in the paper tables. Individual level fertility data are available for Kisesa (Magu) and uMkhanyakude (Africa Centre) on the INDEPTH data repository <http://www.indepth-ishare.org/index.php/home>. Other data are not publicly available due to ethical restrictions but requests can be made to the individual study sites: TAZAMA cohort study urassamark@yahoo.co.uk, the Africa Centre info@africacentre.ac.za, MRC Uganda mrc@mrcuganda.org and UVRI directoruvri@uvri.go.ug.

Abstract

Background

UNAIDS official estimates of national HIV prevalence are based on trends observed in antenatal clinic surveillance, after adjustment for the reduced fertility of HIV positive women. Uptake of ART may impact on the fertility of HIV positive women, implying a need to re-estimate the adjustment factors used in these calculations. We analyse the effect of antiretroviral therapy (ART) provision on population-level fertility in Southern and East Africa, comparing trends in HIV infected women against the secular trends observed in uninfected women.

Methods

We used fertility data from four community-based demographic and HIV surveillance sites: Kisesa (Tanzania), Masaka and Rakai (Uganda) and uMkhanyakude (South Africa). All births to women aged 15–44 years old were included in the analysis, classified by mother's age and HIV status at time of birth, and ART availability in the community. Calendar time period of data availability relative to ART Introduction varied across the sites, from 5 years prior to ART roll-out, to 9 years after. Calendar time was classified according to ART availability, grouped into pre ART, ART introduction (available in at least one health facility serving study site) and ART available (available in all designated health facilities serving study site). We used Poisson regression to calculate age adjusted fertility rate ratios over time by HIV status, and investigated the interaction between ART period and HIV status to ascertain whether trends over time were different for HIV positive and negative women.

Results

Age-adjusted fertility rates declined significantly over time for HIV negative women in all four studies. However HIV positives either had no change in fertility (Masaka, Rakai) or experienced a significant increase over the same period (Kisesa, uMkhanyakude). HIV

Funding: The ALPHA network is core funded by Wellcome Trust WT090959MA.

Competing Interests: The authors have declared that no competing interests exist.

positive fertility was significantly lower than negative in both the pre ART period (age adjusted fertility rate ratio (FRR) range 0.51 95%CI 0.42–0.61 to 0.73 95%CI 0.64–0.83) and when ART was widely available (FRR range 0.57 95%CI 0.52–0.62 to 0.83 95%CI 0.78–0.87), but the difference has narrowed. The interaction terms describing the difference in trends between HIV positives and negatives are generally significant.

Conclusions

Differences in fertility between HIV positive and HIV negative women are narrowing over time as ART becomes more widely available in these communities. Routine adjustment of ANC data for estimating national HIV prevalence will need to allow for the impact of treatment.

Background

There has been a rapid scale up in the provision of Antiretroviral therapy (ART) in Sub Saharan Africa in the last decade with more than 7.5 million people receiving treatment by the end of 2012 [1] this comes hand in hand with increased access to HIV testing and therefore knowledge of HIV status. A large proportion of those with HIV in sub Saharan Africa are women of reproductive age who are routinely tested for HIV at antenatal care clinics (ANC) in order to try to prevent mother to child transmission and those testing positive are referred to clinics for treatment [2].

Official estimates of national HIV prevalence by UNAIDS are currently based on trends observed in antenatal clinic surveillance [3] and far more ANC data are becoming available due to routine reports from PMTCT programs. ANC prevalence trends are then adjusted to match prevalence levels estimated from national population surveys [4]. Part of this adjustment accounts for the reduced fertility of HIV positive women [5, 6], however increased access to care and treatment services and uptake of antiretroviral therapy may impact on the fertility of HIV positive women for biological and behavioural reasons, implying a need to re-estimate the adjustment factors used in these calculations.

There have been no longitudinal studies in Sub-Saharan Africa that have looked at the population level impact of ART on fertility. A few studies have measured fertility or incidence of pregnancy in women on ART [7–10] but these lack suitable comparators (HIV negative women in the same community) and may not be representative of all HIV positive women. A cross sectional comparison using Malawian Demographic and Health Survey data (DHS) found an increased probability of giving birth for HIV positive women relative to HIV negative women between 2004 and 2010 [11] which is attributed to the increase in access to mother to child transmission and ART services in Malawi. We analyse the effect of antiretroviral therapy provision on population-level fertility in four cohort studies in Southern and East Africa, comparing trends in HIV infected women against the secular trends observed in uninfected women.

Methods

Sites and setting

Fertility data that span the pre-ART era and the time of introduction and widespread use of ART are available from four community-based demographic and HIV surveillance sites: Kisesa (managed by the National Institute of Medical Research Mwanza in Northern Tanzania),

Masaka (MRC/UVRI Uganda Research Unit on AIDS), Rakai (Rakai Health Sciences)—both in South-west Uganda, and uMkhanyukude (Africa Centre, in KwaZulu-Natal, South Africa). These sites belong to the network for analysing longitudinal population based data on HIV in Africa (ALPHA)[12, 13] and have been described in detail elsewhere [14–20].

Data, HIV and ART provision

The ALPHA network standardises site-specific data to a common format to enable joint analysis. In brief, each study records demographic data including dates of birth (of mothers and infants). The studies also collect data on HIV status and provide dates of testing and test results for their populations. In Kisesa, Rakai, and uMkhanyakude, the HIV surveys were done separately to the demographic surveillance rounds, and data were linked afterwards using unique identifiers. In Masaka, HIV testing was done immediately after demographic surveillance rounds which were used to list those eligible for HIV testing. HIV testing took place in the home for all sites apart from Kisesa where temporary village clinics are used to which people are transported from their homes. Prior to the availability of antiretroviral therapy, testing protocols used informed consent without disclosure, so that participants did not learn the results of the HIV research tests, however with the advent of ART, sites began to offer full pre-test and post-test counselling to the participants during the data collection round. Participants are still not obliged take part in the counselling or to learn their results. In Rakai the samples taken in the home were tested at the field laboratory and then returned by a community based counselor to those participants requesting the results.

The introduction and level of uptake of ART in the different studies varies. ART was introduced in the study areas between 2004 and 2005, when selected clinics were allowed to administer drugs and people were mobilised to make them aware of the new services. Further details of ART introduction and uptake are described elsewhere[21–24].

Study Population

The population included in this analysis is women of reproductive age (15–44) living in the surveillance areas between the time point corresponding to five years before ART was introduced, to the last date for which data were available for each site up to 2015. [Table 1](#) shows prevalence for each site in pre and post ART years for women aged 15–49.

All live births to women aged 15–44 years old while under observation in the study were included in the analysis, classified by mother's age, area of residence and HIV status at time of the birth, and by ART availability in the community. We did not include 45–49 year olds to create the standard fertility analysis grouping of 15–49 years as there were very few births to HIV positive women at this age.

All sites are predominately rural, though most contain areas with local markets, health and education facilities. Area of residence is classified differently for each site. The Masaka DSS is divided into two areas: old villages where surveillance began in 1989; and new villages where surveillance began in November 1999. In Kisesa sub-villages are classified according to their distance from the small trading centre on the main road. In Rakai the peri urban group comprises trading towns, villages along secondary roads and fishing communities and the rural category are communities beyond those located along secondary roads. uMkhanyakude is predominantly rural but also includes an small town and peri-urban densely populated areas.

Measures

HIV Status was classified as negative, positive and unknown. Negative person time was defined as the time between first testing negative and last testing negative, also included in negative

Table 1. HIV prevalence of women aged 15–49 in Study sites.

Study Site, Round (years)	ART period	N	Prevalence	(95% CI)
Kisesa 4 (2003–2004)	Pre ART	3369	5.11	(4.36–5.85)
Kisesa 6 (2010–2010)	Post ART	2445	7.08	(6.06–8.09)
Manicaland 3 (2003–2005)	Pre ART	8273	20.45	(19.58–21.32)
Manicaland 5 (2009–2011)	Post ART	6150	17.54	(16.59–18.50)
Masaka 14 (2002–2003)	Pre ART	2361	14.06	(12.66–15.46)
Masaka 16 (2004–2005)	Post ART	2485	17.99	(16.48–19.50)
Rakai 9 (2002–2003)	Pre ART	3708	13.65	(12.54–14.75)
Rakai 12 (2006–2008)	Post ART	4507	14.98	(13.93–16.02)
uMkhanyakude 1 (2002–2005)	Pre ART	6533	27.2	(26.12–28.28)
uMkhanyakude 4 (2007–2008)	Post ART	3604	27.58	(26.12–29.04)

doi:10.1371/journal.pone.0151877.t001

time was a site specific time following the last negative test, this was allocated according to the HIV incidence rates in the sites, the cut off for post negative time was taken as the time at which the cumulated probability of becoming infected following the last test reached 5%. This cut-off point was five years in Kisesa, Masaka and Rakai and two years in uMkhanyakude. HIV positive time was all the person time after the first positive test. The sero conversion interval was calculated as the mid point between first positive and last negative test and positive and negative time was assigned accordingly. Interval censoring was invoked if the midpoint of the sero conversion interval was longer than the site specific post negative time—in that case only the post negative time was assigned to negative and one year pre positive time was assigned to positive, the remainder of the interval was designated unknown. The composition of the unknown group over time changes due to the different ways HIV positive and HIV negative time is allocated and is also affected by participation changes in testing [25, 26] therefore we do not present results from this group. No pressure was put on participants to receive their HIV status as part of research survey procedures, therefore we would not expect a link between participation in testing and fertility.

Calendar time period of data availability relative to ART introduction varied across the sites (Fig 1), from 5 years prior to ART roll-out, to 9 years after. Calendar time was classified according to ART availability, grouped into pre ART, ART Introduction (introduced in at least one of the health facilities serving the community) and ART available (available in all the health facilities serving the community that were designated as ART providers according to national guidelines). We limit results presented for the short ART roll out period to just the age specific rates, as this time period is relatively short and is different in each site depending on the speed and nature of the roll out therefore tells us little about general patterns and trends.

Analysis

We used Poisson regression to calculate age adjusted fertility rate ratios over time by HIV status, and investigated the interaction between ART period and HIV status to ascertain whether trends over time were different for HIV positive and negative women. We adjust for age and area of residence in this analysis to control for any changes in the composition of the study site that may have occurred between the pre and post ART periods. The analysis was performed separately for each site and pooled across sites where appropriate, the pooled results were adjusted by study site.

At ages under 20 HIV infection and fertility are highly correlated as many teenagers will not yet have had sex, and only those who have had sex are at risk of becoming pregnant or




Fig 1. Dates of ART Periods included in the analysis.

doi:10.1371/journal.pone.0151877.g001

acquiring HIV. Therefore fertility in the 15–19 year old age group is almost always higher in HIV positive women [6]. We therefore stratify our analysis to look at 15–19 year olds and 20–44 year olds separately.

Ethics statements

Each of the six sites contributing data to the pooled analysis has received ethical clearance from the appropriate local ethics review bodies, and from the corresponding Institutional Review Boards for studies which had collaborating partnerships with Northern Universities.

uMkhanyakude. Annually re-certified ethics permission for the Africa Centre DSS and nested individual HIV surveillance among consenting adults is obtained from the Biomedical Research Ethics Committee at the Nelson Mandela School of Medicine, University of Kwa-Zulu-Natal. Detailed written informed consent obtained for participation in the HIV surveillance.

Kisesa. Ethical approval for each survey round of the Kisesa cohort study granted by the Tanzanian Medical Research Coordinating Committee and the Ethics Committee of the London School of Hygiene and Tropical Medicine. Prior to 2006, verbal consent was obtained directly from all study participants (aged 15 and over), due to low literacy rates among the study population. Consent was witnessed and documented for each study participant by a member of the sero-survey team or senior person from the community. From 2006 onward, consent was again obtained directly from all study participants, however a written consent option was introduced, for those able to provide this and written parental consent for those under 18 years was also obtained.

Masaka. The MRC DSS is approved by the Uganda Virus Research Institute (UVRI) Science and Ethics Committee (SEC) and the Uganda National Council of Science and Technology (UNCST). Study participants provided written consent to participate in all parts of the study.

Rakai. The Rakai Community Cohort Survey is approved by the UVRI SEC and UNCST. Literate participants provided written consent while those unable to read or write had a witness

sign on their behalf. Those unable to read or write used a thumbprint to document consent and a witness would also sign as evidence that the consent had been read to the participant who had understood and consented to participate.

Results

Overall crude and age specific fertility rates fell or remained the same between the pre and post ART periods for all sites (Tables 2–5). Classifying the crude fertility rates by HIV status shows that overall fertility declined in the HIV negative but remained more or less the same or increased slightly for the HIV positive (For the HIV positive in Rakai this is true if we exclude 15–19 year olds). Age specific rates by HIV status follow this general trend for all sites apart from slight increases in HIV negative 25–34 year olds in Masaka, 35–39 year olds in Rakai and 15–19 year olds in uMkhanyakude. Overall fertility is higher in the rural areas for all sites.

Fertility rates in HIV positive women are consistently lower than those of HIV negative women apart from the youngest age group of 15–19 years olds (Fig 2). For all sites apart from uMkhanyakude fertility rates in HIV positive women aged over 20 are around half those of the negatives in the pre ART period and 0.73 (95%CI 0.64–0.83) times the negative rates in uMkhanyakude. In the post ART period overall the differences between positive and negative are smaller, with rate ratios ranging from 0.57 (95%CI 0.52–0.62) in Rakai to 0.83 (95%CI 0.78–0.87) in uMkhanyakude. In both periods fertility differences between positive and negative women become greater as age increases.

For all women aged 15–44 years old, age and residence adjusted fertility rates declined significantly over time, driven by the significant decline in fertility among HIV negative women in all four studies (Table 6). For HIV positive women in Kisesa and Masaka there is a fertility increase of borderline significance of 1.21(95%CI 0.99–1.49) and 1.16(95%CI 0.96–1.41) respectively, and no change in uMkhanyakude and Rakai. The interaction term between HIV Status and ART period was significant for all sites apart from uMkhanyakude showing that the changes in fertility over the two ART periods are significantly different for HIV positive and HIV negative women. Excluding 15–19 year olds (Table 7) whose fertility rates are determined largely by patterns of sexual debut, yields an overall reduction in fertility in HIV negative women in all sites and increases among HIV positive women in Kisesa and Masaka with rate ratios of 1.29 (95%CI 1.04–1.59) and 1.21 (95%CI 0.99–1.47) respectively, and no change in uMkhanyakude and Rakai. In this narrower age range the interaction terms between HIV Status and ART period were significant for all sites apart from Rakai.

The data for 20–44 year olds were pooled for the comparison of the period when ART was available with the pre ART period, giving overall rate ratios of 0.9 (95%CI 0.89–0.92) for HIV negative women and 1.08 (95%CI 1.01–1.16) for HIV positive women adjusted for age, residence and study site, with a significant interaction ($p < 0.001$) between HIV status and ART period. Focussing on 15–19 year olds (Table 8), there has been a significant reduction in fertility for HIV negative women in all sites apart from uMkhanyakude where the relative increase was 1.11 (95%CI 1.01–1.22). The confidence intervals for the rate ratios for the HIV positive are very large, so no real pattern can be determined.

For the two sites with data available (Kisesa and Masaka) in the 5–10 years prior to ART there was no evidence of any interaction between HIV status and period when comparing the periods 0–5 years and 5–10 years prior to ART (Not shown).

Person years with unknown HIV status were lowest in Masaka at 7.2% in the pre ART period and 8.2% in the post ART period, in Rakai they were 20.2% and 27.7%, Kisesa 28.9% and 52.0%, uMkhanyakude 46.5% and 38.3% respectively. The HIV status unknown category includes the unclassified post negative time intervals and time before the first HIV test.

Table 2. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Kisesa.

	All			HIV-Negative			HIV-Positive		
	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000
Kisesa									
ART Period									
Pre ART	5253	26.2	200.1	4108	17.6	233.1	132	1.0	126.9
ART Introduction	3715	19.5	190.6	2763	12.6	218.4	106	0.8	132.0
ART available	5895	37.2	158.3	2924	15.4	190.3	195	1.4	144.2
Age									
<i>15–19</i>									
Pre ART	846	6.2	136.6	584	3.6	160.2	12	0.1	197.6
ART Introduction	518	4.8	108.3	308	2.9	107.3	8	0.0	232.3
ART available	792	9.5	83.6	335	3.6	93.3	4	0.0	81.5
<i>20–24</i>									
Pre ART	1461	5.4	270.8	1117	3.4	325.8	23	0.2	144.7
ART Introduction	952	3.8	250.7	714	2.3	309.2	9	0.1	97.5
ART available	1475	7.2	205.1	637	2.7	237.1	24	0.1	193.6
<i>25–29</i>									
Pre ART	1294	4.9	264.1	1002	3.2	311.7	44	0.3	157.6
ART Introduction	897	3.3	270.1	676	2.1	315.3	34	0.2	202.7
ART available	1402	6.3	223.9	693	2.4	285.1	40	0.2	185.5
<i>30–34</i>									
Pre ART	877	4.0	221.3	705	2.8	254.3	38	0.3	143.7
ART Introduction	746	3.1	237.7	563	2.1	272.0	32	0.2	133.3
ART available	1131	5.6	200.5	621	2.4	254.7	66	0.3	197.1
<i>35–39</i>									
Pre ART	569	3.3	173.6	510	2.6	198.8	13	0.2	80.4
ART Introduction	426	2.4	180.9	356	1.7	212.8	16	0.2	102.2
ART available	805	5.0	162.5	454	2.3	201.2	55	0.4	131.9
<i>40–44</i>									
Pre ART	206	2.5	81.8	190	2.0	95.0	2	0.1	17.3
ART Introduction	176	2.1	83.9	146	1.6	92.3	7	0.1	62.6
ART available	290	3.7	78.1	184	2.0	93.7	6	0.2	28.3
Residence									
<i>Rural</i>									
Pre ART	3125	13.4	233.2	2564	10.1	254.2	71	0.4	171.0
ART Introduction	2295	9.9	232.0	1805	7.2	252.4	54	0.3	162.7
ART available	3453	17.9	193.0	1932	8.9	215.9	103	0.6	164.3
<i>Peri Urban/Urban</i>									
Pre ART	2128	12.8	165.7	1544	7.5	204.8	61	0.6	97.6
ART Introduction	1420	9.6	147.9	958	5.5	174.2	52	0.5	110.4
ART available	2442	19.3	126.3	992	6.4	154.6	92	0.7	126.8

doi:10.1371/journal.pone.0151877.t002

Discussion

This analysis uses community based cohort studies to look at the population impact of ART on fertility. We have shown that changes in fertility have been different in HIV positive women compared to the HIV negative over the pre and post ART Period—representing a discontinuity since the pre ART era. This would indicate that the introduction of ART is narrowing the gap

Table 3. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Masaka.

	All			HIV-Negative			HIV-Positive		
	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000
Masaka									
ART Period									
Pre ART	2524	14.8	170.1	2285	12.8	179.2	117	1.0	115.2
ART Introduction	510	3.3	153.6	466	2.8	164.0	21	0.3	83.8
ART available	4185	28.0	149.7	3672	23.3	157.4	281	2.3	119.7
Age									
<i>15–19</i>									
Pre ART	490	4.6	107.0	448	4.2	106.9	14	0.1	205.3
ART Introduction	101	1.0	105.3	91	0.9	102.3	2	0.0	112.2
ART available	665	8.5	78.5	593	7.6	77.6	25	0.2	159.4
<i>20–24</i>									
Pre ART	766	2.9	261.3	701	2.5	277.6	32	0.2	185.3
ART Introduction	155	0.6	245.1	145	0.5	266.8	3	0.0	77.3
ART available	1115	4.9	226.6	1005	4.1	242.6	58	0.3	186.8
<i>25–29</i>									
Pre ART	562	2.4	231.9	497	2.0	252.0	38	0.3	136.5
ART Introduction	126	0.5	229.9	115	0.4	260.9	6	0.1	101.3
ART available	1012	4.3	237.1	884	3.5	256.1	71	0.4	163.7
<i>30–34</i>									
Pre ART	357	1.9	192.4	316	1.5	211.9	20	0.2	88.8
ART Introduction	69	0.4	154.4	63	0.4	175.6	4	0.1	69.3
ART available	786	4.0	195.3	680	3.2	215.4	71	0.5	133.5
<i>35–39</i>									
Pre ART	263	1.7	152.8	241	1.4	168.4	11	0.2	62.7
ART Introduction	38	0.4	98.4	32	0.3	100.4	5	0.0	117.7
ART available	466	3.3	139.6	387	2.6	149.6	47	0.5	92.1
<i>40–44</i>									
Pre ART	86	1.3	64.9	82	1.1	71.7	2	0.1	20.9
ART Introduction	21	0.3	60.4	20	0.3	68.9	1	0.0	29.0
ART available	141	2.9	48.1	123	2.3	52.6	9	0.4	22.2
Residence									
<i>Original Study Villages</i>									
Pre ART	1989	11.3	175.5	1820	9.9	183.6	81	0.7	116.5
ART Introduction	382	2.4	158.1	347	2.1	164.8	16	0.2	97.8
ART available	3003	19.5	153.7	2675	16.6	161.4	182	1.5	121.4
<i>New villages</i>									
Pre ART	535	3.5	152.7	465	2.8	163.8	36	0.3	112.4
ART Introduction	128	0.9	141.6	119	0.7	161.6	5	0.1	57.4
ART available	1182	8.4	140.5	997	6.8	147.6	99	0.8	116.7

doi:10.1371/journal.pone.0151877.t003

in fertility rates between the HIV positive and negative. These results are similar to those found in the cross sectional study using the Malawi DHS [11] which showed a decrease over two surveys in the relative difference in fertility comparing the HIV positive and HIV negative at the time of the survey. Since our longitudinal data can accurately measure HIV status at the time of birth these results are a strong affirmation of the cross-sectional findings.

Table 4. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for Rakai.

	All			HIV-Negative			HIV-Positive		
	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000
Rakai									
ART Period									
Pre ART	6598	51.8	127.3	5805	35.9	161.8	495	5.5	90.2
ART Introduction	2598	23.1	112.5	2304	15.5	148.5	201	2.3	88.6
ART available	6634	68.7	96.6	5736	42.8	134.0	547	6.9	79.3
Age									
<i>15–19</i>									
Pre ART	1220	13.4	91.3	1119	8.1	137.3	38	0.3	131.0
ART Introduction	310	5.7	54.8	273	3.0	90.7	7	0.1	83.9
ART available	674	17.4	38.8	601	9.2	65.2	17	0.2	90.8
<i>20–24</i>									
Pre ART	2320	12.8	181.4	2090	9.6	217.9	137	1.1	127.4
ART Introduction	872	5.4	161.6	799	3.8	208.7	50	0.4	129.5
ART available	1953	14.8	131.8	1651	9.0	183.0	125	0.9	139.0
<i>25–29</i>									
Pre ART	1713	10.3	166.7	1460	7.3	199.5	183	1.6	116.7
ART Introduction	791	4.8	165.2	693	3.5	199.0	80	0.6	133.4
ART available	1992	13.7	145.9	1641	8.6	190.0	178	1.6	112.6
<i>30–34</i>									
Pre ART	830	6.4	128.8	684	4.4	156.5	96	1.3	74.6
ART Introduction	425	3.4	124.9	369	2.4	155.8	40	0.6	65.0
ART available	1309	10.9	119.7	1077	6.8	158.5	131	1.7	75.4
<i>35–39</i>									
Pre ART	382	4.8	79.0	331	3.4	96.4	36	0.8	45.4
ART Introduction	155	2.0	76.0	130	1.5	88.9	19	0.3	55.1
ART available	572	7.1	80.3	458	4.3	106.1	65	1.3	50.8
<i>40–44</i>									
Pre ART	133	4.1	32.4	121	3.0	40.2	5	0.5	10.5
ART Introduction	45	1.8	24.9	40	1.4	29.3	5	0.2	21.0
ART available	134	4.8	28.1	116	2.9	40.3	7	0.8	8.4
Residence									
<i>Rural</i>									
Pre ART	5483	41.2	133.2	4872	29.3	166.4	390	4.2	91.9
ART Introduction	2200	18.2	121.1	1979	12.6	157.3	157	1.7	91.7
ART available	5156	49.7	103.7	4459	31.7	140.8	400	4.7	85.9
<i>Peri Urban/Urban</i>									
Pre ART	1115	10.7	104.5	933	6.6	141.4	105	1.2	84.3
ART Introduction	398	4.9	80.7	325	2.9	110.7	44	0.6	79.1
ART available	1401	18.5	75.7	1019	8.9	114.7	118	1.8	65.1

doi:10.1371/journal.pone.0151877.t004

Fertility dynamics, HIV and changes due to ART are complex and can be both biological and behavioural. Earlier studies showed that HIV positive women with further disease progression have lower fertility than the uninfected and those more recently infected [9, 10, 27]. Women with HIV also have increased risk of spontaneous abortion and still birth [28] which lower their fertility. It is possible that the improved health of women on ART increases their

Table 5. Fertility of women aged 15–44 years old, by calendar time period and stratified by individual HIV status for uMkhanyakude.

	All			HIV-Negative			HIV-Positive		
	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000	Births	Person Years	Rate /1000
uMkhanyakude									
ART Period									
Pre ART	3337	31.8	104.8	1550	14.0	110.7	297	3.0	98.3
ART Introduction	3899	33.7	115.7	1887	15.3	123.6	581	4.9	119.1
ART available	11601	119.5	97.0	4741	41.0	115.7	2264	23.7	95.4
Age									
<i>15–19</i>									
Pre ART	794	9.3	85.2	485	5.9	82.6	45	0.4	120.7
ART Introduction	1019	9.8	104.2	664	6.4	103.4	85	0.4	196.8
ART available	2836	32.8	86.4	1639	17.3	94.5	217	1.4	159.3
<i>20–24</i>									
Pre ART	1014	6.6	154.5	435	2.4	182.2	95	0.7	138.7
ART Introduction	1262	7.4	169.6	589	3.2	182.4	211	1.1	184.9
ART available	3749	25.2	149.0	1631	9.3	175.4	587	4.2	140.2
<i>25–29</i>									
Pre ART	653	4.8	135.3	209	1.3	167.0	77	0.7	116.3
ART Introduction	689	4.9	139.5	228	1.3	170.4	133	1.0	129.4
ART available	2398	20.3	118.2	661	4.5	145.5	680	5.6	122.0
<i>30–34</i>									
Pre ART	491	4.1	121.0	206	1.2	168.9	47	0.5	86.7
ART Introduction	505	4.2	119.5	184	1.2	158.3	95	0.9	103.1
ART available	1487	15.9	93.8	397	3.0	132.4	483	5.1	94.7
<i>35–39</i>									
Pre ART	284	3.6	79.9	154	1.5	104.6	27	0.4	64.8
ART Introduction	301	3.7	80.6	148	1.4	106.0	43	0.8	57.0
ART available	880	13.5	65.2	305	3.1	99.0	240	4.2	56.8
<i>40–44</i>									
Pre ART	101	3.5	28.7	61	1.8	34.0	6	0.3	17.4
ART Introduction	123	3.6	34.3	74	1.7	42.9	14	0.6	23.3
ART available	251	11.9	21.1	108	3.7	29.2	57	3.3	17.3
Residence									
<i>Rural</i>									
Pre ART	2069	18.9	109.8	1076	9.6	112.2	165	1.6	100.3
ART Introduction	2382	19.8	120.2	1288	10.3	124.9	335	2.7	123.9
ART available	6955	66.2	105.1	3220	26.8	120.4	1190	12.2	97.7
<i>Peri Urban/Urban</i>									
Pre ART	1192	12.2	97.5	452	4.2	107.1	126	1.3	95.0
ART Introduction	1387	12.6	110.0	548	4.6	118.9	234	2.0	114.8
ART available	4476	48.4	92.5	1486	13.7	108.3	1048	10.8	97.1

doi:10.1371/journal.pone.0151877.t005

fecundity although one study found an increase in still births for HIV positive women on ART compared to those not on ART[29].

Relationship dynamics may also change: studies from the pre ART era have shown an increased risk of widowhood and marital dissolution for HIV positive women and low rates of remarriage [30, 31], therefore decreasing their chances to bear more children. In the era of




Fig 2. Unadjusted fertility rate ratios by age and ART period comparing positives to negatives.

doi:10.1371/journal.pone.0151877.g002

ART the risk of widowhood will decrease and marital dissolution rates may change leading to more opportunity for childbearing.

Fertility intentions are likely also to change, HIV positive women are more likely to report desiring fewer births than those uninfected[32] but some studies that compared fertility intentions of HIV positive women on treatment to those not on treatment found an increase in desire for children with increasing duration on ART [7, 8, 33]. It is unclear whether these intentions translate into actual increases in fertility. A cross sectional study from a perinatal HIV Research Unit in Soweto found no difference in fertility intentions between those on ART or not[34]—however all participants were attending the HIV clinic so according to the authors, the intentions of those not yet on treatment may have been shaped by the knowledge that ART was available when needed. A multicounty HIV care and treatment program cohort study in sub-Saharan Africa reported HIV positive women on treatment having 1.74(95%CI 1.19–2.54) higher incidence of pregnancy than those not on treatment[9]. The study was unable to determine the factors underlying the results with both biological and behavioural factors being possible.

Table 6. Fertility Rate Ratio (FRR) for 15–44 year olds comparing ART period with pre ART adjusted for by age and residence.

ART Period	HIV Negative		HIV Positive		Interaction p-value*
	FRR	(95% CI)	FRR	(95% CI)	
<i>Kisesa</i>					
Pre-ART	1		1		
ART Available	0.84	(0.81–0.88)	1.21	(0.99–1.49)	0.001
<i>Masaka</i>					
Pre-ART	1		1		
ART Available	0.90	(0.86–0.94)	1.16	(0.96–1.41)	0.010
<i>uMkhanyakude</i>					
Pre-ART	1		1		
ART Available	0.98	(0.93–1.03)	1.04	(0.92–1.16)	0.363
<i>Rakai</i>					
Pre-ART	1		1		
ART Available	0.84	(0.81–0.86)	0.96	(0.86–1.08)	0.020

*Interaction between ART period and HIV status

doi:10.1371/journal.pone.0151877.t006

This analysis shows the extent of changes in fertility trends at the population level which is important for modellers and policy makers. It does not tell us how much of the change is attributable to biological factors directly associated with improved health of those receiving ART, psychological changes that alter fertility intentions, or social changes in marital dynamics and stigma. It is important to note that in the pre ART era most people in these studies would not have known their HIV status so reasons for low fertility in the HIV positives would not include a conscious desire for fewer children motivated by knowledge of status. These topics need further analysis with individual linkage to clinic data to classify time on treatment, to investigate biological factors, and more detailed demographic and behavioural background characteristics.

Differences in fertility between HIV positive and HIV negative women are narrowing over time as ART becomes more widely available in these communities. Routine adjustment of

Table 7. Fertility Rate Ratio (FRR) for 20–44 year olds comparing ART period with pre ART adjusted for by age and residence.

ART Period	HIV Negative		HIV Positive		Interaction p-value*
	FRR	(95% CI)	FRR	(95% CI)	
<i>Kisesa</i>					
Pre-ART	1		1		
ART Available	0.89	(0.86–0.93)	1.29	(1.04–1.59)	0.001
<i>Masaka</i>					
Pre-ART	1		1.00		
ART Available	0.94	(0.90–0.99)	1.21	(0.99–1.47)	0.016
<i>uMkhanyakude</i>					
Pre-ART	1		1		
ART Available	0.90	(0.84–0.95)	1.04	(0.92–1.17)	0.033
<i>Rakai</i>					
Pre-ART	1		1		
ART Available	0.93	(0.90–0.96)	1.00	(0.89–1.12)	0.252

*Interaction between ART period and HIV status

doi:10.1371/journal.pone.0151877.t007

Table 8. Fertility Rate Ratio (FRR) for 15–19 year olds comparing ART period with pre ART adjusted for by age and residence.

ART Period	HIV Negative		HIV Positive		Interaction p-value*
	FRR	(95% CI)	FRR	(95% CI)	
<i>Kisesa</i>					
Pre-ART	1		1		
ART Available	0.56	(0.49–0.64)	0.40	(0.14–1.12)	0.524
<i>Masaka</i>					
Pre-ART	1		1		
ART Available	0.75	(0.67–0.85)	0.73	(0.41–1.32)	0.936
<i>uMkhanyakude</i>					
Pre-ART	1		1		
ART Available	1.11	(1.01–1.22)	1.32	(0.97–1.79)	0.278
<i>Rakai</i>					
Pre-ART	1		1		
ART Available	0.49	(0.44–0.53)	0.66	(0.38–1.13)	0.277

*Interaction between ART period and HIV stat

doi:10.1371/journal.pone.0151877.t008

ANC data for estimating national HIV prevalence will need to allow for the impact of treatment. Given the profound differences between fertility rate ratios and trends in infected and uninfected women under 20 with those aged 20 and over, it would be useful to classify ANC data on HIV prevalence by age, reporting separately on those under 20.

Acknowledgments

This paper is written on behalf of the ALPHA network:

Principle investigators:

Steve Tollman (Agincourt), Agincourt, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Honorati Masanja (Ifakara), Ifakara Health Institute, Dar-Es-Salaam, Tanzania. Amelia Crampin (Karonga), Malawi Epidemiology and Intervention Research Unit, London School of Hygiene and Tropical Medicine, Lilongwe, Malawi. Mark Urassa, (Kisesa) Tazama Project, Tanzania National Institute for Medical Research, Mwanza, Tanzania. Daniel Kwaro (Kisumu), Kisumu, Kenya Medical Research Institute and the Centers for Disease Control, Kisumu, Kenya. Simon Gregson (Manicaland), Manicaland HIV/STD prevention project, Biomedical Research and Training Institute, Harara, Zimbabwe and School of Public Health, Imperial College, London, UK. Pontiano Kaleebu (Masaka), MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. Alex Ezech (Nairobi), African Population and Health Research Center, Nairobi, Kenya. Tom Lutalo (Rakai), Rakai Health Sciences Program, Uganda Virus Research Institute, Rakai, Uganda. Deenan Pillay (uMkhanyakude), Univ KwaZulu Natal, Wellcome Trust Africa Ctr Hlth & Population Studies, Durban, South Africa.

Grant Holders:

Basia Zaba, Jim Todd, Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK. Samuel J Clark, Department of Sociology, University of Washington, Seattle WA, USA. Victoria Hosegood, Department of Social Statistics and Demography, Southampton University, Southampton, UK.

Pooled Analysis Group:

Basia Zaba, Milly Marston, Emma Slaymaker, Georges Reniers, Alison Wringe, Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK. Victoria

Hosegood, Department of Social Statistics and Demography, Southampton University, Southampton, UK. Samuel J Clark, Department of Sociology, University of Washington, Seattle WA, USA. Kobus Herbst Africa Centre for Health and Population Studies, University of KwaZulu Natal, Somkhele, South Africa.

Lead Author on behalf of the ALPHA network:

Milly Marston, Department of Population Health, London School of Hygiene and Tropical Medicine, London, UK. Email: milly.marston@lshtm.ac.uk

Details of the ALPHA Network are found at alpha.lshtm.ac.uk.

Author Contributions

Analyzed the data: MM. Contributed reagents/materials/analysis tools: VH TL JN BM MM.

Wrote the paper: MM BZ VH TL JN.

References

1. WHO U. Global update on HIV treatment 2013: results, impact and opportunities. Geneva: World Health Organization, 2013.
2. Baggaley R, Hensen B, Ajose O, Grabbe KL, Wong VJ, Schilsky A, et al. From caution to urgency: the evolution of HIV testing and counselling in Africa. *Bulletin of the World Health Organization*. 2012; 90(9):652–8B. doi: [10.2471/BLT.11.100818](https://doi.org/10.2471/BLT.11.100818) PMID: [22984309](https://pubmed.ncbi.nlm.nih.gov/22984309/); PubMed Central PMCID: [PMC3442388](https://pubmed.ncbi.nlm.nih.gov/PMC3442388/).
3. surveillance UWwgoGHAaS. Guidelines for conducting HIV sentinel serosurveys among pregnant women and other groups. 2003.
4. Marsh K, Mahy M, Salomon JA, Hogan DR. Assessing and adjusting for differences between HIV prevalence estimates derived from national population-based surveys and antenatal care surveillance, with applications for Spectrum 2013. *AIDS*. 2014; 28 Suppl 4:S497–505. doi: [10.1097/QAD.0000000000000453](https://doi.org/10.1097/QAD.0000000000000453) PMID: [25203158](https://pubmed.ncbi.nlm.nih.gov/25203158/); PubMed Central PMCID: [PMC4247262](https://pubmed.ncbi.nlm.nih.gov/PMC4247262/).
5. Lewis JJ, Ronsmans C, Ezeh A, Gregson S. The population impact of HIV on fertility in sub-Saharan Africa. *AIDS*. 2004; 18 Suppl 2:S35–43. PMID: [15319742](https://pubmed.ncbi.nlm.nih.gov/15319742/).
6. Zaba B, Gregson S. Measuring the impact of HIV on fertility in Africa. *AIDS*. 1998; 12 Suppl 1:S41–50. PMID: [9677188](https://pubmed.ncbi.nlm.nih.gov/9677188/).
7. Homsy J, Bunnell R, Moore D, King R, Malamba S, Nakityo R, et al. Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. *PLoS One*. 2009; 4(1):e4149. doi: [10.1371/journal.pone.0004149](https://doi.org/10.1371/journal.pone.0004149) PMID: [19129911](https://pubmed.ncbi.nlm.nih.gov/19129911/); PubMed Central PMCID: [PMC2612743](https://pubmed.ncbi.nlm.nih.gov/PMC2612743/).
8. Maier M, Andia I, Emenyonu N, Guzman D, Kaida A, Pepper L, et al. Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. *AIDS Behav*. 2009; 13 Suppl 1:28–37. doi: [10.1007/s10461-008-9371-7](https://doi.org/10.1007/s10461-008-9371-7) PMID: [18389364](https://pubmed.ncbi.nlm.nih.gov/18389364/); PubMed Central PMCID: [PMC3606959](https://pubmed.ncbi.nlm.nih.gov/PMC3606959/).
9. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. *PLoS medicine*. 2010; 7(2):e1000229. doi: [10.1371/journal.pmed.1000229](https://doi.org/10.1371/journal.pmed.1000229) PMID: [20161723](https://pubmed.ncbi.nlm.nih.gov/20161723/); PubMed Central PMCID: [PMC2817715](https://pubmed.ncbi.nlm.nih.gov/PMC2817715/).
10. Nguyen RH, Gange SJ, Wabwire-Mangen F, Sewankambo NK, Serwadda D, Wawer MJ, et al. Reduced fertility among HIV-infected women associated with viral load in Rakai district, Uganda. *Int J STD AIDS*. 2006; 17(12):842–6. doi: [10.1258/095646206779307586](https://doi.org/10.1258/095646206779307586) PMID: [17212863](https://pubmed.ncbi.nlm.nih.gov/17212863/).
11. Souza E, Moultrie T. Estimating the effect of HIV/AIDS on fertility among Malawian women using demographic and health survey data. *African Journal of AIDS Research*. 2015; 14(4):315–21.
12. Maher D, Biraro S, Hosegood V, Isingo R, Lutalo T, Mushati P, et al. Translating global health research aims into action: the example of the ALPHA network. *Tropical medicine & international health: TM & IH*. 2010; 15(3):321–8. doi: [10.1111/j.1365-3156.2009.02456.x](https://doi.org/10.1111/j.1365-3156.2009.02456.x) PMID: [20070637](https://pubmed.ncbi.nlm.nih.gov/20070637/).
13. Reniers G, Wamukoya M, Urassa M, Nyaguara A, Nakiyingi-Miuro J, Lutalo T, et al. Data Resource Profile: Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA Network). *International journal of epidemiology*. 2016. doi: [10.1093/ije/dyv343](https://doi.org/10.1093/ije/dyv343) PMID: [26968480](https://pubmed.ncbi.nlm.nih.gov/26968480/).
14. Biraro S, Morison LA, Nakiyingi-Miuro J, Whitworth JA, Grosskurth H. The role of vertical transmission and health care-related factors in HIV infection of children: a community study in rural Uganda. *J Acquir Immune Defic Syndr*. 2007; 44(2):222–8. doi: [10.1097/QAI.0b013e31802e2954](https://doi.org/10.1097/QAI.0b013e31802e2954) PMID: [17179771](https://pubmed.ncbi.nlm.nih.gov/17179771/).

15. Mwaluko G, Urassa M, Isingo R, Zaba B, Boerma JT. Trends in HIV and sexual behaviour in a longitudinal study in a rural population in Tanzania, 1994–2000. *AIDS*. 2003; 17(18):2645–51. doi: [10.1097/01.aids.0000088225.55968.9d](https://doi.org/10.1097/01.aids.0000088225.55968.9d) PMID: [14685059](https://pubmed.ncbi.nlm.nih.gov/14685059/).
16. Shafer LA, Biraro S, Nakyingi-Miiri J, Kamali A, Ssematimba D, Ouma J, et al. HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989–2005. *AIDS*. 2008; 22(13):1641–9. doi: [10.1097/QAD.0b013e32830a7502](https://doi.org/10.1097/QAD.0b013e32830a7502) PMID: [18670225](https://pubmed.ncbi.nlm.nih.gov/18670225/).
17. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. *Science*. 2013; 339(6122):966–71. doi: [10.1126/science.1228160](https://doi.org/10.1126/science.1228160) PMID: [23430656](https://pubmed.ncbi.nlm.nih.gov/23430656/); PubMed Central PMCID: [PMC4255272](https://pubmed.ncbi.nlm.nih.gov/PMC4255272/).
18. Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *International Journal of Epidemiology*. 2008; 37(5):956–62. doi: [10.1093/ije/dym211](https://doi.org/10.1093/ije/dym211) PMID: [WOS:000259771500010](https://pubmed.ncbi.nlm.nih.gov/WOS:000259771500010/).
19. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Paxton L, Berkley S, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. *AIDS*. 1998; 12(10):1211–25. PMID: [9677171](https://pubmed.ncbi.nlm.nih.gov/9677171/).
20. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. *Lancet*. 1999; 353(9152):525–35. PMID: [10028980](https://pubmed.ncbi.nlm.nih.gov/10028980/).
21. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, et al. Cohort Profile: Hlabisa HIV Treatment and Care Programme. *International Journal of Epidemiology*. 2011; 40(2):318–26. doi: [10.1093/ije/dyp402](https://doi.org/10.1093/ije/dyp402) PMID: [WOS:000289165800010](https://pubmed.ncbi.nlm.nih.gov/WOS:000289165800010/).
22. Kasamba I, Baisley K, Mayanja BN, Maher D, Grosskurth H. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999–2009. *Tropical Medicine & International Health*. 2012; 17(8):e66–e73. doi: [10.1111/j.1365-3156.2012.02841.x](https://doi.org/10.1111/j.1365-3156.2012.02841.x)
23. Makumbi FE, Nakigozi G, Reynolds SJ, Ndyanabo A, Lutalo T, Serwadda D, et al. Associations between HIV Antiretroviral Therapy and the Prevalence and Incidence of Pregnancy in Rakai, Uganda. *AIDS research and treatment*. 2011; 2011:519492. doi: [10.1155/2011/519492](https://doi.org/10.1155/2011/519492) PMID: [21490780](https://pubmed.ncbi.nlm.nih.gov/21490780/); PubMed Central PMCID: [PMC3066572](https://pubmed.ncbi.nlm.nih.gov/PMC3066572/).
24. Wringe A, Floyd S, Kazooba P, Mushati P, Baisley K, Urassa M, et al. Antiretroviral therapy uptake and coverage in four HIV community cohort studies in sub-Saharan Africa. *Tropical Medicine & International Health*. 2012; 17(8):e38–e48. doi: [10.1111/j.1365-3156.2011.02925.x](https://doi.org/10.1111/j.1365-3156.2011.02925.x)
25. Floyd S, Molesworth A, Dube A, Crampin AC, Houben R, Chihana M, et al. Underestimation of HIV prevalence in surveys when some people already know their status, and ways to reduce the bias. *AIDS*. 2013; 27(2):233–42. doi: [10.1097/QAD.0b013e32835848ab](https://doi.org/10.1097/QAD.0b013e32835848ab) PMID: [22842993](https://pubmed.ncbi.nlm.nih.gov/22842993/).
26. Reniers G, Eaton J. Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys. *AIDS*. 2009; 23(5):621–9. doi: [10.1097/QAD.0b013e3283269e13](https://doi.org/10.1097/QAD.0b013e3283269e13) PMID: [19182677](https://pubmed.ncbi.nlm.nih.gov/19182677/); PubMed Central PMCID: [PMC2695508](https://pubmed.ncbi.nlm.nih.gov/PMC2695508/).
27. Lee LM, Wortley PM, Fleming PL, Eldred LJ, Gray RH. Duration of human immunodeficiency virus infection and likelihood of giving birth in a Medicaid population in Maryland. *Am J Epidemiol*. 2000; 151(10):1020–8. PMID: [10853641](https://pubmed.ncbi.nlm.nih.gov/10853641/).
28. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. *British journal of obstetrics and gynaecology*. 1998; 105(8):836–48. PMID: [9746375](https://pubmed.ncbi.nlm.nih.gov/9746375/).
29. Chen JY, Ribaud HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. *The Journal of infectious diseases*. 2012; 206(11):1695–705. doi: [10.1093/infdis/jis553](https://doi.org/10.1093/infdis/jis553) PMID: [23066160](https://pubmed.ncbi.nlm.nih.gov/23066160/); PubMed Central PMCID: [PMC3488194](https://pubmed.ncbi.nlm.nih.gov/PMC3488194/).
30. Porter L, Hao L, Bishai D, Serwadda D, Wawer MJ, Lutalo T, et al. HIV status and union dissolution in sub-Saharan Africa: the case of Rakai, Uganda. *Demography*. 2004; 41(3):465–82. PMID: [15461010](https://pubmed.ncbi.nlm.nih.gov/15461010/).
31. Terceira N, Gregson S, Zaba B, Mason P. The contribution of HIV to fertility decline in rural Zimbabwe, 1985–2000. *Popul Stud (Camb)*. 2003; 57(2):149–64. doi: [10.1080/0032472032000097074](https://doi.org/10.1080/0032472032000097074) PMID: [12888411](https://pubmed.ncbi.nlm.nih.gov/12888411/).
32. Nattabi B, Li J, Thompson SC, Orach CG, Earnest J. A systematic review of factors influencing fertility desires and intentions among people living with HIV/AIDS: implications for policy and service delivery. *AIDS Behav*. 2009; 13(5):949–68. doi: [10.1007/s10461-009-9537-y](https://doi.org/10.1007/s10461-009-9537-y) PMID: [19330443](https://pubmed.ncbi.nlm.nih.gov/19330443/).
33. Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. *AIDS patient care and STDs*. 2007; 21(4):278–85. doi: [10.1089/apc.2006.0108](https://doi.org/10.1089/apc.2006.0108) PMID: [17461723](https://pubmed.ncbi.nlm.nih.gov/17461723/).

34. Kaida A, Laher F, Strathdee SA, Janssen PA, Money D, Hogg RS, et al. Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. *American journal of public health*. 2011; 101(2):350–8. doi: [10.2105/AJPH.2009.177469](https://doi.org/10.2105/AJPH.2009.177469) PMID: [20403884](https://pubmed.ncbi.nlm.nih.gov/20403884/); PubMed Central PMCID: PMC3020203.